AstraZeneca (AZN) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS
AstraZeneca (NYSE:AZN) announced its earnings results on Thursday. The company reported $1.21 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.27 by $0.06, Stock Ratings Network reports. The company had revenue of $6.25 billion for the quarter, compared to the consensus estimate of $6.45 billion. During the same quarter last year, the company posted $1.51 earnings per share. AstraZeneca’s revenue was down 6.5% compared to the same quarter last year.
AstraZeneca (NYSE:AZN) traded down 1.51% during mid-day trading on Thursday, hitting $52.76. 386,534 shares of the company’s stock traded hands. AstraZeneca has a 52 week low of $44.17 and a 52 week high of $53.73. The stock has a 50-day moving average of $51.5 and a 200-day moving average of $50.73. The company has a market cap of $66.056 billion and a P/E ratio of 13.67.
Several analysts have recently commented on the stock. Analysts at Bank of America Corp. upgraded shares of AstraZeneca from an “underperform” rating to a “neutral” rating in a research note to investors on Monday. They now have a $55.20 price target on the stock, up previously from $48.82. On a related note, analysts at Jefferies Group downgraded shares of AstraZeneca from a “hold” rating to an “underperform” rating in a research note to investors on Friday, October 11th. Finally, analysts at Leerink Swann reiterated a “market perform” rating on shares of AstraZeneca in a research note to investors on Monday, September 30th. Five research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $53.73.
AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.